Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now?
Although the destruction of diarthrodial joints has long been a focus of arthritis research, we still know extremely little about the metabolism of joint tissues in vivo and how this may change in arthritis. The use of skeletal imaging, particularly radiographic analysis, and more recently, magnetic resonance imaging, has provided much insight into the consequences of the disease process, namely the destruction of cartilage in rheumatoid arthritis (RA) and osteoarthritis (OA), juxta-articular bone destruction (erosions and osteopenia) in RA, and extensive bone remodelling (sclerosis) in OA. But such analyses tell us little about the disease processes that lead to these skeletal changes.
We cartilages'2 and very much increased contents in synovial fluids over levels in blood'0 suggest that increased synthesis followed by degradation of newly synthesised molecules is a key feature of both these diseases. These markers may also be useful in detecting decreased synthesis, such as that associated with joint immobilisation.'4 Cartilage collagen synthesis is reflected by the release of the C-propeptide of type II procollagen into serum in development,'5 and synovial body fluids in arthritis.'6 Degradation of type II collagen can now also be measured. 17 These markers are now available for studies in arthritis.
The 145 kDa cartilage matrix protein is absent from articular cartilages and therefore provides the opportunity to study selectively systemic cartilage metabolism.' Moreover, the systemic osteoporosis of RA and the severe juxta-articular osteopenia, a consequence of enhanced bone resorption resulting from an imbalance in RA, can be measured by immunoassayl9-21 or high performance liquid chromatography22 of the urinary hydroxypyridinium crosslinks, derived from cartilage and bone matrix collagens. Even skeletal changes in OA are detectable by elevated cross-links in urine.22 The dominance of bone mass means that these cross-links are probably mainly derived from this tissue. New immunoassays should soon be able to permit collagen cross-link detection in blood.
In contrast, bone synthesis is reflected by the release of osteocalcin, synthesised by osteoblasts. Serum osteocalcin is hardly changed in RA,' probably due to the suppression of synthesis by inflammation. But in OA, the extensive hypertrophy and juxta-articular bone turnover is accompanied by elevated serum osteocalcin (A R Poole, M Ionescu, A Swan and P Dieppe, manuscript in preparation).
Degeneration of cartilages, such as frequently results from post-traumatic injuries, can eventually lead to clinicallydefined OA. Research at the University of Lund in Sweden, headed by Drs Dick Heinegard, Frank Wolheim, Stefan Lohmander and Tore Saxne, together with the work of Drs Eugene Thonar and Klaus Kuettner in Chicago, has pioneered many developments in this field. The early work of Dick Heinegard's group was the first to use immunoassays to study cartilage marker molecules. 23 The Lund group drew attention to alterations in cartilage turnover in RA" and following traumatic injuries to articular tissues such as cruciate ligaments and menisci. 24 25 In this issue of the journal they describe a study of the cartilage oligomeric protein (COMP),26 a member of the thrombospondin family, first identified by Fife and Brandt27 and cloned by Heinegard's group.2" Like aggrecan, this molecule is significantly elevated in synovial fluid after traumatic joint injury. The elevations of both aggrecan and COMP persist, albeit often at lower levels, and are a characteristic feature of post-traumatic OA. The reported elevations in serum aggrecan in OA,29 30 directly from the elevated levels of TGF-3 in these inflamed joints and the lack of inhibition of synthesis by cytokines such as IL-I and TNF-ot.
The development and use of these new immunological assays to identify 'markers' of joint metabolism and disease is still in its infancy. They hold much promise in studying skeletal development. In arthritis research, we need to rigorously assess these markers by their use in carefullycontrolled clinical trials. We must study sub-groups characterised by clearly recognisable differences in disease activity. Establishment of the molecular bases of their production, correlations with well-defined clinical parameters and with each other are essential if we are to understand their true significance and explore their value fully. Too little has so far been done in these areas. Too much emphasis has been placed in earlier work on the measurement of levels of single markers, often with little regard to clinical changes and to each other, and to the molecular mechanisms regulating their release.
But their use is already helping us to a better understanding of the pathobiology of these diseases in vivo. The bone markers have been shown to have considerable potential in the study of osteoporosis and metastasis to bone. Other markers may be of considerable benefit in identifying more appropriate therapy, especially in early disease. As in other areas of clinical research, they should help us not only evaluate the effectiveness of therapy but provide a basis for the development of new therapies, designed to control inflammation and damage to skeletal tissues, stimulate repair, and overall, help us achieve improved management of these diseases. 
